We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been making waves in the biopharmaceutical industry with its flagship product, Rezdiffra, a treatment for non-alcoholic steatohepatitis (NASH).

BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq ... hypersomnia (IH), will be presented in a poster session at the American Academy of Neurology ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After a phase 3 trial win, Madrigal Pharmaceuticals reckons it could succeed where so many other companies have failed, and finally bring a drug to market to treat the liver disease non-alcoholic ...

Madrigal Pharmaceuticals has a 12 month low of $189.00 and a 12 month high of $377.46. Madrigal Pharmaceuticals ( NASDAQ:MDGL – Get Free Report ) last posted its earnings results on Wednesday ...

It’s another standard of excellence in cinema—and we’d argue that there’s indeed correlation between great posters and great films. Consider: In our (admittedly wildly unscientific!) ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges.

PORT ST. LUCIE, Fla. — New York Mets infielder Nick Madrigal could miss the entire 2025 season with a fractured left shoulder. Manager Carlos Mendoza told reporters Friday that Madrigal needs surgery ...